Kane Biotech Inc. announced that it has filed a patent on its revyveTM Antimicrobial Wound Gel Spray, a follow-on product to its FDA 510 (k) cleared revyveTM Antimicrobial Wound Gel, and will be introducing it at the Boswick Burn and Wound Care Symposium.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.13 CAD | 0.00% | -3.70% | +62.50% |
1st Jan change | Capi. | |
---|---|---|
+62.50% | 12.52M | |
+49.41% | 56.95B | |
+41.65% | 40.26B | |
-6.72% | 39.32B | |
-5.96% | 28.37B | |
+12.99% | 26.45B | |
-19.82% | 19.41B | |
+32.35% | 12.54B | |
-0.08% | 12.15B | |
+25.18% | 12.21B |
- Stock Market
- Equities
- KNE Stock
- News Kane Biotech Inc.
- Kane Biotech Inc. Files New Patent on Revyvetm Antimicrobial Wound Gel Spray